← Eichor
Condition: Metastatic Cutaneous Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Cutaneous Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT03889899A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune Syst
Phase 2 · 38 location(s) · National Cancer Institute (NCI) · NCT07042295Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Intratumoral N17350 in Advanced Solid Tumors
Phase 1/Phase 2 · 8 location(s) · Onchilles Pharma Inc · NCT07339176Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT04534127Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
NA · 1 location(s) · David Palma · NCT07337161Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Phase 1 · 5 location(s) · Ankyra Therapeutics, Inc · NCT06171750A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06305962(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Phase 1 · 1 location(s) · Eben Rosenthal · NCT05747625Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692TIL Therapy in cSCC and MCC
Phase 2 · 1 location(s) · Karam Khaddour, MD, MS · NCT07288073A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
Phase 2 · 7 location(s) · Salzburger Landeskliniken · NCT04204837Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Phase 1 · 1 location(s) · Emory University · NCT04428671Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
NA · 2 location(s) · Alpha Tau Medical LTD. · NCT04068155
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.